On Apr. 13, 2020, RedHill Biopharma announced the first two patients were treated with opaganib at a leading hospital in Israel.

At the time of treatment initiation, both patients suffered from moderate to severe acute respiratory symptoms related to SARS-CoV-2 infection, required supplemental oxygenation and were hypoxic despite being treated with maximum flow of oxygen with cannulas.